A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

End-Stage Renal Disease

Interventions

DRUG

Rivaroxaban 15 mg

Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.

Trial Locations (1)

Knoxville